secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001213900-24-068597
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q2 net income $3.0M; OLC NDA on track for August 2024
---------------------------------------------------------------

- OLC pivotal trial: 1.4% discontinuation rate (evaluable) for treatment-related AEs; no SAEs.
- Patient survey: 79% preferred OLC, 98% found it easy to take, 89% satisfied.
- UNI-494 Phase 1 enrollment completed; data expected Q3 2024; new patent granted until 2040.
- R&D expenses $4.9M (up $2.6M YoY); cash $41.8M, sufficient into 2026.
- Diluted EPS loss $0.15; basic EPS $0.08 due to warrant liability fair value change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024068597/0001213900-24-068597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390024068597/ea0211321-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-068597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer